Methods of treatment using IL-31RA

• US 9,139,651 B2
• Filed: 01/07/2011
• Issued: 09/22/2015
• Est. Priority Date: 02/14/2005
• Status: Active Grant

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Bilsborough, Janine
• Primary Examiner(s): STANFIELD, CHERIE MICHELLE
• Application Number:
  US12/986,707
• Publication Number:
  US 20110117052A1
• Time in Patent Office: 1,719 Days
• Field of Search: 424/85.2
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/10 Anti-acne agents
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/7155 for interleukins [IL]
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.

Claims

1. A method of treating a patient with prurigo nodularis, comprising administering a therapeutically effective amount of a soluble IL-31RA homodimeric receptor to the patient, wherein the soluble IL-31RA homodimeric receptor comprises amino acid residues 20-519 of SEQ ID NO:

6 fused to the Fc region of an immunoglobulin.

2. The method of claim 1, wherein the immunoglobulin Fc region is of IgG, IgA, IgD, IgM or IgE.

3. The method of claim 1, wherein the soluble IL-31RA homodimeric receptor binds with an IL-31 polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:

2.